Is Opus Genetics, Stock a Good Investment?
Opus Genetics, Investment Advice | IRD |
- Examine Opus Genetics,'s financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Opus Genetics,'s leadership team and their track record. Good management can help Opus Genetics, navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceutical Products space and any emerging trends that could impact Opus Genetics,'s business and its evolving consumer preferences.
- Compare Opus Genetics,'s performance and market position to its competitors. Analyze how Opus Genetics, is positioned in terms of product offerings, innovation, and market share.
- Check if Opus Genetics, pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Opus Genetics,'s stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Opus Genetics, stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Opus Genetics, is a good investment.
Sell | Buy |
Sell
Market Performance | Very Weak | Details | |
Volatility | Extremely Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Very Weak | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Opus Genetics, Stock
Researching Opus Genetics,'s stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company had not issued any dividends in recent years.
To determine if Opus Genetics, is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Opus Genetics,'s research are outlined below:
| Opus Genetics, may become a speculative penny stock | |
| Opus Genetics, had very high historical volatility over the last 90 days | |
| Opus Genetics, has high likelihood to experience some financial distress in the next 2 years | |
| Opus Genetics, was previously known as Ocuphire Pharma and was traded on NASDAQ Exchange under the symbol OCUP. | |
| The company reported the last year's revenue of 19.05 M. Reported Net Loss for the year was (9.99 M) with profit before taxes, overhead, and interest of 0. | |
| Opus Genetics, generates negative cash flow from operations | |
| Opus Genetics, has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from investing.com: Opus Genetics president Benjamin Yerxa acquires 9,834 in stock |
Basic technical analysis of Opus Stock
As of the 2nd of December, Opus Genetics, holds the Coefficient Of Variation of (13,981), risk adjusted performance of 0.0029, and Variance of 22.27. Opus Genetics, technical analysis gives you tools to exploit past prices in attempt to determine a pattern that determines the direction of the company's future prices. Please check Opus Genetics, standard deviation, as well as the relationship between the maximum drawdown and kurtosis to decide if Opus Genetics, is priced some-what accurately, providing market reflects its current price of 1.11 per share. Given that Opus Genetics, is a hitting penny stock territory we advise to closely look at its jensen alpha.Opus Genetics,'s insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Opus Genetics, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Opus Genetics,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Opus Genetics, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Yerxa Benjamin R over a week ago Acquisition by Yerxa Benjamin R of 10000 shares of Opus Genetics, at 0.9834 subject to Rule 16b-3 | ||
Magrath George over a week ago Acquisition by Magrath George of 9706 shares of Opus Genetics, at 1.0244 subject to Rule 16b-3 | ||
Magrath George over two weeks ago Acquisition by Magrath George of 90294 shares of Opus Genetics, at 1.0102 subject to Rule 16b-3 | ||
Yerxa Benjamin R over three weeks ago Acquisition by Yerxa Benjamin R of 332800 shares of Opus Genetics, subject to Rule 16b-3 | ||
Magrath George over a month ago Disposition of 37050 shares by Magrath George of Opus Genetics, at 1.18 subject to Rule 16b-3 | ||
Bennett Jean over a month ago Insider Trading | ||
Bennett Jean over a month ago Insider Trading |
Understand Opus Genetics,'s technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Opus Genetics,'s various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0029 | |||
| Market Risk Adjusted Performance | (0.01) | |||
| Mean Deviation | 3.31 | |||
| Coefficient Of Variation | (13,981) | |||
| Standard Deviation | 4.72 | |||
| Variance | 22.27 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.34) | |||
| Total Risk Alpha | (0.83) | |||
| Treynor Ratio | (0.02) | |||
| Maximum Drawdown | 29.54 | |||
| Value At Risk | (6.02) | |||
| Potential Upside | 8.91 | |||
| Skewness | 0.2756 | |||
| Kurtosis | 2.39 |
| Risk Adjusted Performance | 0.0029 | |||
| Market Risk Adjusted Performance | (0.01) | |||
| Mean Deviation | 3.31 | |||
| Coefficient Of Variation | (13,981) | |||
| Standard Deviation | 4.72 | |||
| Variance | 22.27 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.34) | |||
| Total Risk Alpha | (0.83) | |||
| Treynor Ratio | (0.02) | |||
| Maximum Drawdown | 29.54 | |||
| Value At Risk | (6.02) | |||
| Potential Upside | 8.91 | |||
| Skewness | 0.2756 | |||
| Kurtosis | 2.39 |
Consider Opus Genetics,'s intraday indicators
Opus Genetics, intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Opus Genetics, stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Opus Genetics, time-series forecasting models is one of many Opus Genetics,'s stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Opus Genetics,'s historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Opus Stock media impact
Far too much social signal, news, headlines, and media speculation about Opus Genetics, that are available to investors today. That information is available publicly through Opus media outlets and privately through word of mouth or via Opus internal channels. However, regardless of the origin, that massive amount of Opus data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Opus Genetics, news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Opus Genetics, relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Opus Genetics,'s headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Opus Genetics, alpha.
Opus Genetics, Corporate Management
| Joseph MBA | Chief Officer | Profile | |
| Bernhard MBA | Senior Secretary | Profile | |
| Ashwath Jayagopal | Chief Officer | Profile | |
| Bindu Manne | Head Commercialization | Profile | |
| MAcc CPA | Senior Finance | Profile | |
| Nirav CFA | Chief Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Opus Genetics,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Opus Stock refer to our How to Trade Opus Stock guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Opus Genetics,. If investors know Opus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Opus Genetics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Opus Genetics, is measured differently than its book value, which is the value of Opus that is recorded on the company's balance sheet. Investors also form their own opinion of Opus Genetics,'s value that differs from its market value or its book value, called intrinsic value, which is Opus Genetics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Opus Genetics,'s market value can be influenced by many factors that don't directly affect Opus Genetics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Opus Genetics,'s value and its price, as these two are different measures arrived at by various means. Investors typically determine if Opus Genetics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Opus Genetics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.